Abstract Session 12

Co-Chair(s)

• 

  Damian Green, MD (he/him/his)

  Chief, Division of Transplantation and Cellular Therapy
  Sylvester Comprehensive Cancer Center/University of Miami
  Miami, Florida, United States
• 

  Mehmet Samur, PhD

  Senior Research Scientist
  Dana-Farber Cancer Institute, United States

Presentations:

• 11:15 AM – 11:27 AM East Coast USA Time

  OA – 09: Mezigdomide enhances activity of BCMA-targeted cellular and T-cell engager therapies and mitigates immune toxicity in preclinical models of multiple myeloma
  

  Speaker: Marta Larrayoz, PhD (she/her/hers) – University of Navarra
• 11:27 AM – 11:39 AM East Coast USA Time

  OA – 24: A novel mouse model engineered with human immune system is a translationally-important model for studies related to immune-microenvironment and immunotherapies in multiple myeloma
  

  Speaker: Phaik Ju Teoh, PhD – Cancer Science Institute of Singapore, National University of Singapore
• 11:39 AM – 11:51 AM East Coast USA Time

  OA – 66: Cytotoxic CD4+ T cells are major drivers of side effects and response after chimeric antigen receptor T cells against BCMA
  

  Speaker: David Fandrei, MSc – University Leipzig Medical Center, Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, Leipzig, Germany
• 11:51 AM – 12:03 PM East Coast USA Time

  OA – 33: LILRB4 is a promising dual target for tumor cells and immunosuppressive myeloid cells in multiple myeloma
  

  Speaker: Lixin Gong, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
• 12:03 PM – 12:15 PM East Coast USA Time

  OA – 37: Targeting LILRB1 to Sensitize Human Myeloma to Ferroptosis by Disrupting Cholesterol Homeostasis
  

  Speaker: Qiang Wang (he/him/his) – Houston Methodist Research Institute